8-K: Revelation Biosciences Initiates Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences has commenced its Phase 1b clinical study of Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD), with topline data expected mid-year.

Summary

• Revelation Biosciences has started its PRIME Phase 1b clinical study of Gemini in CKD patients.
• The study is a US-based, multi-site, placebo-controlled trial involving up to 40 patients in five cohorts receiving single escalating doses.
• Top-line data, including safety, tolerability, and biomarkers of target activity, are expected by mid-year.
• The company held a special meeting of stockholders on January 17, 2025, where proposals including a reverse stock split and a change of domicile were voted on.
• Stockholders approved the reverse stock split, reservation and issuance of shares related to warrants, and adjournment of the special meeting if needed.
• The proposal to change the company's domicile from Delaware to Nevada did not receive the required number of affirmative votes.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the initiation of the Phase 1b clinical study and the potential of Gemini to address a significant unmet medical need. However, the failure of the domicile change proposal and the inherent risks associated with clinical trials temper the overall sentiment.

Positives

• The initiation of the Phase 1b clinical study of Gemini represents progress in the GEM-CKD program.
• Positive Phase 1 clinical data for intravenous treatment with Gemini has already been announced.
• The company met the primary safety endpoint in the Phase 1 study, and results demonstrated statistically significant pharmacodynamic activity.
• Stockholders approved the reverse stock split, reservation and issuance of shares related to warrants, and adjournment of the special meeting if needed.

Negatives

• The proposal to change the company's domicile from Delaware to Nevada did not receive the required number of affirmative votes.
• The reverse stock split could negatively impact the share price.

Risks

• The forward-looking statements in the press release are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include competition, the ability to manage growth, the successful development of product candidates, and the outcome of clinical studies.
• There are risks relating to adverse safety events, changes in laws, and the ability to maintain the NASDAQ listing.

Future Outlook

Revelation Biosciences anticipates topline data from the PRIME clinical study by mid-year, which will support future development in the GEM-CKD and GEM-AKI programs.

Management Comments

• James Rolke, Chief Executive Officer of Revelation, stated he is delighted to see the Revelation teams hard work culminating with the start of the PRIME study.
• James Rolke stated they look forward to the results and plan to educate the public over the next few months on the importance of the planned biomarkers as it relates to CKD treatment and prevention of AKI.

Industry Context

The announcement highlights Revelation Biosciences' focus on trained immunity and its potential application in treating chronic kidney disease, a significant global health issue. The company is positioning Gemini as a novel approach to reduce inflammation and slow the progression of CKD, potentially addressing a large unmet medical need.

Comparison to Industry Standards

• Other companies developing treatments for CKD include AstraZeneca (Farxiga), Bayer (Kerendia), and Travere Therapeutics (Filspari).
• These treatments often focus on managing blood sugar, blood pressure, or reducing proteinuria.
• Gemini's approach of reprogramming the innate immune system to reduce inflammation is a novel approach compared to these existing treatments.
• The Phase 1b study will provide initial data on the safety, tolerability, and biomarkers of Gemini, which will be compared to existing treatments and other investigational therapies in development.

Stakeholder Impact

• Shareholders: The initiation of the clinical study could positively impact shareholder value if the results are promising.
• Patients: The study offers potential new treatment options for CKD patients.
• Employees: The study provides opportunities for employees to contribute to the development of a novel therapy.
• The reverse stock split could negatively impact shareholder value.

Next Steps

• Revelation Biosciences will continue the PRIME Phase 1b clinical study, enrolling patients and monitoring their safety and tolerability.
• The company will analyze the data collected from the study and prepare for future development in the GEM-CKD and GEM-AKI programs.
• The company will educate the public on the importance of the planned biomarkers as it relates to CKD treatment and prevention of AKI.

Key Dates